Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q13956
UPID:
CNCG_HUMAN
Alternative names:
-
Alternative UPACC:
Q13956; Q52LY7
Background:
The Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma plays a pivotal role in the visual signal transmission and amplification in vertebrate rods and cones. This protein is essential for the proper functioning of phototransduction, a process critical for vision.
Therapeutic significance:
Linked to Cone dystrophy, retinal 3A, a rare eye disorder, this protein's study offers insights into novel therapeutic approaches. Understanding its function and the impact of genetic variants could lead to breakthrough treatments for this and potentially other retinal diseases.